Cartesian Therapeutics (RNAC) EBITDA (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of EBITDA data on file, last reported at -$26.5 million in Q1 2026.

• On a quarterly basis, EBITDA fell 21.06% year-over-year to -$26.5 million in Q1 2026; TTM through Mar 2026 was -$148.0 million, a 182.27% decrease from a year earlier, with the FY2025 full-year figure at -$143.4 million, down 226.69% from the prior year.
• EBITDA for Q1 2026 stood at -$26.5 million, up from -$78.6 million in the prior quarter.
• Over the last five years, EBITDA for RNAC reached as high as $13.9 million in Q2 2022 and fell as low as -$78.6 million in Q4 2025.
• Historically, EBITDA has averaged -$16.8 million across 5 years, with a median of -$18.4 million in 2023.
• Across the five-year window, EBITDA soared 2966.37% in 2022 and slumped 717.07% in 2023, its largest moves.
• Year by year, EBITDA stood at -$8.5 million in 2022, then sank by 327.64% to -$36.3 million in 2023, then increased by 26.43% to -$26.7 million in 2024, then plunged by 194.19% to -$78.6 million in 2025, then jumped by 66.3% to -$26.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$26.5 million in Q1 2026, -$78.6 million in Q4 2025, and -$21.1 million in Q3 2025.